Catalyze: Product Definition for Small Molecules and Biologics - Preliminary Product/Lead Series Identification (R33 - Clinical Trial Not Allowed)

Ceiling: $350,000
Applications Due: Closed
Federal
US Department of Health & Human Services (National Institutes of Health)

This funding opportunity supports early-stage research to develop new therapeutic agents for heart, lung, blood, and sleep disorders, specifically targeting projects that have identified promising small molecules or biologics ready for preclinical testing.

Description

This Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to identify a lead compound series toward development of potential therapeutic agents to treat heart, lung, blood, and sleep diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical optimization and development of therapeutic agents.

Eligibility
States
All
Regions
All
Eligible Entities
State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal organizations, Public housing authorities, Native American tribal organizations, Nonprofits

Funding

Program Funding
Visit Source
Award Ceiling
$350,000
Award Floor
Visit Source
Award Count

Timing

Posted Date
January 24, 2022
App Status
No Longer Accepting Applications
Pre-app Deadline
Visit Source
Application Deadline
November 21, 2024

Funder

Funding Source
Visit Source
Source Type
Federal
Contact Name
NIH OER Webmaster
Contact Email
Click to email
Contact Phone
--

Why Organizations Trust GrantExec

$78.81B
Available Funding
7,151
Active Grants
224
New Grants Analyzed This Week